Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

The TV ad will run through Nov. 16 across major cable channels, including CNN, Fox News and ESPN, a BMS spokesperson told ...

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with ...

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine ...

CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory systemic sclerosis, with 96% remaining off SSc treatment during follow-up, ...

The Healthcare Businesswomen's Association (HBA) successfully convened the second edition of its annual India Leadership Summit (ILS) at The Lalit Hotel, Mumbai. Under the powerful theme "Winning a ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

DISP-10 is a novel tumor-specific virus and CAR T combination designed to overcome key challenges of applying CAR T therapy to solid tumors DISP-10 has broad potential to target all solid tumors of ...

With footage coming out of Jamaica after major hurricane Melissa made landfall yesterday showing the damage left in the ...

Bristol Myers Squibb showcases new long-term and real-world data from cardiovascular portfolio at the AHA scientific sessions 2025: Princeton, New Jersey Wednesday, November 5, 20 ...